Australia markets closed

Gamida Cell Ltd. (GMDA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.7200+0.5000 (+22.52%)
At close: 04:00PM EST
2.7800 +0.06 (+2.21%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous close2.2200
Open2.3500
Bid0.0000 x 1000
Ask0.0000 x 1200
Day's range2.3500 - 2.8700
52-week range2.1000 - 15.0000
Volume13,921,030
Avg. volume565,596
Market cap161.293M
Beta (5Y monthly)1.90
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Business Wire

    Gamida Cell Provides Update on Omidubicel BLA Submission

    BOSTON, January 19, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, announced that following receipt of positive Type B meeting correspondence from the U.S. Food and Drug Administration (FDA) yesterday, the company plans to initiate a rolling Biologics License Application (BLA) submission for omidubicel, a potentially life-saving treatment for patients with blood cancers in need of stem cell transplant. As previous

  • Business Wire

    Gamida Cell Announces Data to be Presented at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

    BOSTON, January 07, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today announced eight presentations at the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings (TCT) being held in Salt Lake City, UT, from February 2-6, 2022.

  • Business Wire

    Gamida Cell Presents Two-Year Survival Data for GDA-201 and Resource Utilization Analysis for Omidubicel at 63rd ASH Annual Meeting

    BOSTON, December 13, 2021--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today announced that two-year follow-up data for GDA-201, the company’s lead candidate in its NAM-enabled NK cell therapy pipeline, will be presented at the 63rd American Society of Hematology (ASH) Annual Meeting, being held in Atlanta, Georgia. Additionally, for patients who participated in the phase 3 trial of omidubicel, the company will be pr